GTA Construction News staff writer
Sanofi has announced an expansion at its artificial intelligence and data science presence in Toronto with a $294-million investment that will grow its Artificial Intelligence Centre of Excellence and add about 50 new jobs in Ontario’s life sciences sector.
The expansion builds on an existing team of more than 150 employees already working at the Toronto-based AI hub, where the global biopharmaceutical company applies machine learning and advanced analytics to accelerate drug discovery, vaccine development and pharmaceutical research.
Toronto was selected in 2022 as the global base for Sanofi’s AI Centre of Excellence following an international site search, with the company citing the region’s concentration of artificial intelligence talent, research institutions and life sciences expertise. The expansion further anchors that presence in the city’s growing tech and health innovation ecosystem.
The additional investment will deepen its use of artificial intelligence across its research and development pipeline, with a focus on speeding up the path from early-stage discovery to patient treatments. Sanofi has positioned itself as an early adopter of AI in biopharmaceutical development, using digital tools to help identify potential therapies and improve clinical outcomes.
Sanofi has also continued to expand its Canadian footprint more broadly, including the opening of a major biomanufacturing facility in North York in 2024. The company says its operations in Canada contribute to global vaccine supply, with products manufactured in the region used to protect millions of people and exported internationally.
The latest expansion is expected to strengthen collaboration with Ontario universities and support student training opportunities in AI, data science and biomedical research, as the province continues to produce a large pipeline of STEM graduates each year.
Ontario’s life sciences sector has been growing steadily, supported by strong research capacity, a large talent base and increasing private-sector investment in advanced health technologies. The province’s industry generated tens of billions in revenue in 2024, with AI and biomanufacturing identified as key areas of future growth.
Sanofi says the Toronto AI Centre of Excellence will remain central to its strategy of integrating artificial intelligence into drug development, as the company works to bring new medicines and vaccines to market more quickly.
